- Home
- ARDX
ARDX
Ardelyx Inc.
as 03-28-2025 4:00pm EST
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 1.3B | IPO Year: | 2014 |
| Target Price: | $10.61 | AVG Volume (30 days): | 3.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.32 - $9.33 | Next Earning Date: | 05-01-2025 |
| Revenue: | $333,615,000 | Revenue Growth: | 168.06% |
| Revenue Growth (this year): | 14.26% | Revenue Growth (next year): | 32.49% |
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | ARDX | President & CEO | Mar 7 '25 | Sell | $5.36 | 41,668 | $223,198.81 | 1,635,138 | |
| MOTT DAVID M | ARDX | Director | Feb 24 '25 | Buy | $5.00 | 77,729 | $388,738.27 | 2,015,494 | |
| RAAB MICHAEL | ARDX | President & CEO | Feb 20 '25 | Sell | $5.62 | 22,964 | $129,124.28 | 1,635,138 | |
| Renz Justin A | ARDX | Chief Financial Officer | Feb 20 '25 | Sell | $5.62 | 5,171 | $29,076.53 | 285,968 | |
| Williams Laura A | ARDX | Chief Medical Officer | Feb 20 '25 | Sell | $5.62 | 4,941 | $27,783.24 | 303,804 | |
| GRAMMER ELIZABETH A | ARDX | See Remarks | Feb 20 '25 | Sell | $5.62 | 4,291 | $24,128.29 | 181,043 | |
| RAAB MICHAEL | ARDX | President & CEO | Jan 31 '25 | Sell | $5.36 | 41,666 | $223,354.76 | 1,635,138 | |
| MOTT DAVID M | ARDX | Director | Jan 21 '25 | Buy | $4.99 | 199,000 | $992,671.70 | 2,015,494 | |
| RAAB MICHAEL | ARDX | President & CEO | Jan 7 '25 | Sell | $5.31 | 41,666 | $221,308.96 | 1,635,138 |
Latest Ardelyx Inc. News
ARDX Breaking Stock News: Dive into ARDX Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
Simply Wall St.
21 days ago
High Growth Tech Stocks In The US With Promising Potential
MT Newswires
a month ago
BTIG Initiates Ardelyx at Buy With $14 Price Target
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 02/27/2025
Simply Wall St.
a month ago
Ardelyx Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
MT Newswires
a month ago
Ardelyx Says China Approves New Drug Application for Hyperphosphatemia Treatment Tenapanor; Shares Up Pre-Bell
GlobeNewswire
a month ago
Tenapanor Approved in China for Hyperphosphatemia
GlobeNewswire
a month ago
Ardelyx to Participate in Upcoming Investor Conferences
Compare ARDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARDX Ardelyx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.